Clinical trials: Agitated Behaviour
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
Addressing Dementia Via Agitation-Centered Evaluation
This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor
- Trial name
- ADVANCE (NCT03226522)
- Testing
- AXS-05, Bupropion
- Where
- 78 sites in United States, Australia
- Volunteers
- 366 people
- Sponsor
- Axsome Therapeutics, Inc.
Schizophrenia
Staccato Loxapine in Agitation (Proof of Concept)
The purpose of this study is to assess efficacy and safety of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients.
- Trial name
- NCT00369577
- Testing
- Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Alexza Pharmaceuticals, Inc.
Bipolar I Disorder
Staccato Loxapine in Agitated Patients With Bipolar Disorder
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in bipolar 1 disorder patients.
- Trial name
- NCT00721955
- Testing
- Inhaled loxapine 5 mg, Inhaled loxapine 10 mg
- Where
- 6 sites in United States
- Volunteers
- 314 people
- Sponsor
- Alexza Pharmaceuticals, Inc.
Dementia, Alzheimer Disease
The Healthy Patterns Sleep Study
The Healthy Patterns Study intervention is a home-based activity intervention designed to improve symptoms of circadian rhythm disorders (CRD) and quality of life (QOL) in home-dwelling persons with dementia.
- Conditions
- Dementia, Alzheimer Disease, Circadian Rhythm Disorders, Circadian Rhythm Sleep Disorder
- Trial name
- NCT03682185
- Testing
- Attention-Control Condition, Timed Activity Intervention
- Where
- United States
- Volunteers
- 421 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Alzheimer Disease
Valproate in Dementia (VALID)
The purpose of this trial is to demonstrate whether valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not experienced agitation and psychosis in…
- Trial name
- NCT00071721
- Testing
- Valproate
- Where
- 46 sites in United States
- Volunteers
- 313 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Psychosis, Dementia
A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
A ten-week study to assess MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
- Conditions
- Psychosis, Dementia, Aggression, Agitation
- Trial name
- NCT03044249
- Testing
- MP-101
- Where
- 20 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- Mediti Pharma Inc.
Agitation, Dementia
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed [PRN]), for a maximum of 28 doses within a 12-week treatment period.
- Trial name
- NCT05271552
- Testing
- BXCL501
- Where
- 11 sites in United States
- Volunteers
- 151 people
- Sponsor
- BioXcel Therapeutics Inc
Anxiety, Separation, Psychomotor Agitation
Cartoon Distraction and Parental Presence on Anxiety in Pediatric Anesthesia
Nearly 50% of young children undergoing surgery exhibit high level of anxiety during induction of anesthesia because of exposure to unfamiliar environment and people and separation from parents.
- Trial name
- NCT02027844
- Testing
- Cartoon, parental presence
- Where
- South Korea
- Volunteers
- 117 people
- Sponsor
- Yeungnam University College of Medicine
Schizophrenia
A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation
This local registration study is to confirm the hypothesis of the efficacy, tolerability and safety of ziprasidone IM (intramuscular) in the Chinese population with agitation in schizophrenia
- Trial name
- NCT00723606
- Testing
- Intramuscular ziprasidone mesylate, Intramuscular haloperidol
- Where
- 9 sites in China
- Volunteers
- 376 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Child Behavior Disorders
The Inner Garden and Care for Children With Moderate to Severe Agitation
The objective is to compare the care including the solution of ambient sensory biofeedback "Inner Garden", compared to the care without this solution, on the regulation of behavioral disorders during a crisis requiring to take…
- Trial name
- ESSAIMS (NCT04610281)
- Testing
- Inner Garden
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Groupe Hospitalier de la Rochelle Ré Aunis
Sleep Disorders, Circadian Rhythm, Insomnia
Actigraphic Analysis of Treatment Response
The study examines and illustrates the utility of utilizing actigraphic measurements to assess treatment response.
- Conditions
- Sleep Disorders, Circadian Rhythm, Insomnia, Psychomotor Agitation
- Trial name
- NCT00723580
- Testing
- risperidone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Child Psychopharmacology Institute
Agitation,Psychomotor, Dementia
Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
This is an adaptive Phase 1b/2 trial design. It is randomized, double-blind, placebo-controlled, multiple ascending dose study assessing efficacy, pharmacokinetics, safety and tolerability of BXCL-501 dosing in adult (65 years…
- Trial name
- TRANQUILITY (NCT04251910)
- Testing
- Sublingual film containing Dexmedetomidine
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- BioXcel Therapeutics Inc
Agitation, Dementia
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed [PRN]), for a maximum of 168 doses within a 12-week treatment period.
- Trial name
- NCT05665088
- Testing
- BXCL501
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- BioXcel Therapeutics Inc
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute
Agitation, Alzheimer's Disease
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease
The objectives of the study are to evaluate the safety, tolerability and efficacy of AVP-923 compared to placebo, for the treatment of symptoms of agitation in participants with Alzheimer's Disease (AD).
- Trial name
- NCT01584440
- Testing
- AVP-923-20, AVP-923-30
- Where
- 44 sites in United States
- Volunteers
- 220 people
- Sponsor
- Avanir Pharmaceuticals
Delirium, Agitation
Effects of Dexmedetomidine on Delirium Duration of Non-intubated ICU Patients (4D Trial)
The primary purpose of the study is to evaluate whether dexmedetomidine is effective in treating agitated delirium of non-intubated ICI patients
- Trial name
- 4D (NCT03317067)
- Testing
- Dexmedetomidine
- Where
- France
- Volunteers
- 168 people
- Sponsor
- University Hospital, Clermont-Ferrand
Agitation
A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room
In the Psychiatric Emergency Room, agitated patients are treated routinely with an I.M. Haloperidol "cocktail" (Haloperidol 5 mg, Lorazepam 2 mg, Cogentin 2 mg), which has proved to be an effective treatment.
- Trial name
- NCT00457366
- Testing
- Quetiapine, Haloperidol, Lorazepam
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Southern California
Alzheimer's Disease, Agitation
Citalopram for Agitation in Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of citalopram for agitation in Alzheimer's dementia.
- Trial name
- CitAD (NCT00898807)
- Testing
- citalopram
- Where
- 8 sites in United States, Canada
- Volunteers
- 186 people
- Sponsor
- JHSPH Center for Clinical Trials
Alzheimer's Disease, Disruptive Behavior
Prazosin for Agitation in Alzheimer's Disease
The study evaluates the effects of Prazosin on agitation in adults with Alzheimer's disease. Two thirds of the participants will participate in the medication portion, while one third will participate in the placebo portion
- Trial name
- NCT03710642
- Testing
- Prazosin
- Where
- 14 sites in United States
- Volunteers
- 35 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Neurobehavioral Disinhibition
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury
This is a multicenter, randomized, placebo-controlled study to evaluate AVP-786 for the treatment of neurobehavioral disinhibition including aggression, agitation, and irritability in participants with traumatic brain injury…
- Trial name
- NCT03095066
- Testing
- AVP-786-28, AVP-786-42.63
- Where
- 54 sites in United States
- Volunteers
- 168 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.